Analysts Uphold Strong Buy on Liquidia Amid Patent Litigation Concerns
Liquidia Corp’s stock maintains strong buy ratings from analysts despite facing patent litigation, with several firms setting a target price of $29.
2 minutes to read
Liquidia Corp Shines Amid Market Challenges with Potential FDA Approval and Strategic Updates
Liquidia Corporation, a biotech company, is poised for growth with potential FDA approval and a strong presence at industry events, positioning it as a promising investment opportunity amidst market turbulence.
3 minutes to read
Liquidia Corp’s Stock Soars 15% as Yutrepia Launch Clears Legal Hurdles
Liquidia Corp’s stock surged 15% after a court cleared the way for the launch of its drug Yutrepia, a significant milestone for the biotech company.
2 minutes to read
Liquidia Corp’s Stock Soars as Court Clears Yutrepia Launch Amid Regulatory Shifts
Liquidia Corp’s stock surged 15% after a court cleared the way for the launch of its key product Yutrepia, ahead of the company’s upcoming financial results announcement on May 8, 2025.
2 minutes to read